Proprietary bi-functional ADCs target and inhibit unique Delta receptor on tumor-associated Myeloid Derived Suppressor Cells (MDSCs); increasing tumor’s susceptibility to...
Vaxxinity CEO Mei Mei Hu to participate in fireside chat with Sarah Despres, Counselor to the Secretary for Public Health...
Completed Phase 1b/2a trial of VTP-300 met its primary and secondary endpointsVTP-300 is the first antigen-specific immunotherapy shown to induce...
BOSTON, March 28, 2023 (GLOBE NEWSWIRE) -- Covant Therapeutics, an innovative covalent drug discovery company, has entered into an exclusive...
Montrouge, France, March 24, 2023 Ordinary and Extraordinary General Meeting of April 12, 2023 Procedures for Obtaining Information and Preparatory...
Appointment announced today at inaugural Entrepreneurship, Longevity and Biotech Conference Held in Boca RatonBOCA RATON, Fla. and VIENNA, Austria, March...
OXFORD, United Kingdom, March 24, 2023 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC) (the Company, we or us), a clinical-stage...
Reprioritized product portfolio to focus on IV-administered, self-amplifying RNA medicinesOn track to submit IND for ONCR-021 in mid-2023Preclinical data featured...
LAWRENCEVILLE, N.J., March 23, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing DNA-mediated...
Collaboration builds off clinical data demonstrating rigosertib’s activity against PLK1 and may inform a precision medicine approach towards rigosertib’s evaluation...
Media Release 2nd line NSCLC patients refractory to anti-PD-(L)1 treatment have few therapeutic options, and the addition of efti to...
Evaxion’s AI technology has led to the identification of new viral targets for cancer immunotherapyThis potentially enables treatment for patients...
– BBP-398, an investigational SHP2 inhibitor, is a potentially best-in-class therapy for use in combination approaches, which is shown by...
SAN DIEGO, March 23, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed...
WESTLAKE VILLAGE, Calif., March 23, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX) (“Genelux” or “the Company”), a late clinical-stage...
– Initial first-in-human clinical data for IL-2 INDUKINE WTX-124 monotherapy expected in 4Q 2023 from Phase 1/1b clinical trial in...
HAMILTON, BERMUDA, March 22, 2023 (GLOBE NEWSWIRE) -- Preprint of results from animal study shows restriction of tumor growth in...
SOUTH SAN FRANCISCO, Calif., March 22, 2023 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB) today announced that the Compensation Committee of...
Chief Science Officer describes compelling preclinical data supporting continued development of PLACCINE as a differentiated, next-generation vaccine modality LAWRENCEVILLE, N.J.,...
NEW YORK, March 22, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a biotechnology company focused on discovering and...